The myeloma “cure” trials CESAR and ASCENT, which are part of the IMF’s Black Swan Research Initiative® (BSRI) project, are active and ongoing, and I will be providing an update very soon. However, another aspect of the Black Swan project is to understand what causes myeloma and to develop prevention strategies. This is a key element of the iStopMM study, in which full details of patients’ medical history, exposures, and DNA sequence information can be reviewed and assessed. But what questions do we ask? And what clues do we have to guide the discovery process?

Comments

Add new comment